-
1 week ago | 
healio.com | Rob Volansky
Defining and categorizing long COVID has confounded clinicians and researchers since the condition was first identified in the throes of the pandemic, and the challenge continues today. In June 2024, National Academies of Sciences, Engineering and Medicine aimed to define long COVID in all of its various manifestations and iterations. Experts applauded the effort, but they also had questions.
-
1 week ago | 
healio.com | Jill Rollet |Rob Volansky
Traditionally within the purview of rheumatology, gout can appropriately be managed by nephrologists for patients with chronic kidney disease, according to experts who spoke with Healio | Nephrology News & Issues.
-
1 week ago | 
healio.com | John Warrington |Rob Volansky
Move over, PubMed: A new generation of medical data aggregators is using AI to offer health care professionals a different kind of interface and, possibly, a way to the future of accessing health care information. While OpenEvidence has garnered attention due to its partnership with the New England Journal of Medicine, ScopusAI, another research tool using generative AI, has built itself a space using Elsevier’s Scopus peer-reviewed research repository.
-
1 week ago | 
healio.com | Rob Volansky
The mechanisms governing immune-related adverse events resulting from checkpoint inhibition therapy for cancer remain a mystery to rheumatologists and oncologists alike, according to a presenter at the Biologic Therapies Summit.
-
2 weeks ago | 
healio.com | Rob Volansky
Creators of the OpenEvidence AI data aggregation tool have partnered with the New England Journal of Medicine to provide 35 years’ worth of its published content to inform the platform’s answers to medical questions. The move has garnered attention among clinicians and medical researchers alike. “It is so easy to use,” Adam Brown, MD, of the department of rheumatology and immunologic disease at the Cleveland Clinic, said of OpenEvidence in an interview with Healio.
-
2 weeks ago | 
healio.com | Rob Volansky
Vaccines and ongoing vigilance are critical to prevent and manage infections in patients who are immunosuppressed or immunocompromised, according to a presenter at the Biologic Therapies Summit. “This is a never-ending cycle,” Cassandra Calabrese, DO, of the department of rheumatologic and immunologic disease at Cleveland Clinic, told attendees during a presentation that featured information on the prevention and management of hepatitis, HIV, tuberculosis, pneumonia, herpes zoster and COVID-19.
-
2 weeks ago | 
healio.com | Rob Volansky
Read more Recent findings regarding interferon and Janus kinase inhibition may hold clues to improving outcomes in patients with complex myositis, according to a presenter at the Biologic Therapies Summit. “Over the last decade or so, we have seen some successes and failures in myositis,” Rohit Aggarwal, MD, MS, co-director of the Myositis Center, and program director of the Myositis Fellowship Program, at the University of Pittsburgh Medical Center, told attendees.
-
2 weeks ago | 
healio.com | Rob Volansky
Current treatment paradigms for lupus nephritis offer significant room for improvement, according to a presenter at the Biologic Therapies Summit. “Everything you think about lupus nephritis may be wrong,” Michelle Petri, MD, MPH, director of the Hopkins Lupus Center and professor of medicine at Johns Hopkins University, told attendees. As her first example, Petri cited the threshold of 500 mg of protein in the urine as an acceptable benchmark for improvement.
-
2 weeks ago | 
healio.com | Rob Volansky
Despite its pitfalls, social media use can offer some surprising benefits for rheumatologists, according to a presenter at the Biologic Therapies Summit. “‘Dumpster fire’ is a term people throw out a lot when they talk about social media,” Adam J. Brown, MD, of the department of rheumatologic and immunologic disease at the Cleveland Clinic, told attendees.
-
3 weeks ago | 
healio.com | Rob Volansky
Stem cell injections, platelet rich plasma and ivermectin do big business despite dubious or no evidence supporting their use in rheumatology. However, far from being a recent development, this type of “quackery” has a long history in medicine. “The most extreme form of quackery dates back to ancient times, when snake oil salesmen sold products that had no benefit, a high price and potential risk of safety,” Kenneth Saag, MD, MSc, of the University of Alabama at Birmingham, told Healio.
